Investigación
En colaboración continua con laboratorios y asociaciones ofrece a sus pacientes la posibilidad de, en caso de cumplir los criterios de inclusión, entrar en estudios y ensayos de fármacos innovadores.
Contamos con una larga experiencia en la realización de este tipo de estudios dirigidos a pacientes con distintas patologías neurológicas y sin importar lugar de residencia.
Lorem fistrum por la gloria de mi madre esse jarl aliqua llevame al sircoo. De la pradera ullamco qué dise usteer está la cosa muy malar.
CANDID 1263 (Lou Lou) Endpoint Enabling Study in Cyclin-dependent kinase-like 5 Deficiency Disorder (CDD) . CDKL5 Deficiency Disorder (CDD). Observacional
Investigador principal: DR GIL-NAGEL
RAD-GRIN-101 A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Multiple Individually Titrated Doses of Radiprodil in Children with GRIN-related Disorder Radiprodil
Investigador principal: DR GIL-NAGEL
UCB EP0162 A double-blind outpatient study to investigate the efficacy and safety of a single administration of Staccato alprazolam in study participants ≥12 years of age with stereotypical prolonged seizures Stereotypical Prolonged Seizures Alprazolam
Investigador principal: DR GIL-NAGEL
NBI-921352-FOS2021 A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects with Focal Onset Seizures (FOS). NBI-921352
Investigador principal: DR GIL-NAGEL
FENDEEP: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes. Fenfluramina
Investigador principal: DR GIL-NAGEL
1042-TSC-3001 BIORASI A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC) Ganaxolona
Investigador principal: DR GIL-NAGEL
BIA-91067-403 ( ADOPTION ) Estudio aleatorizado, con grupos paralelos, multicéntrico, multinacional, prospectivo, abierto y exploratorio para evaluar el efecto suplementario de 50 mg de opicapona o 100 mg de levodopa como primera estrategia para el tratamiento del deterioro de fin de dosis en pacientes con la enfermedad de Parkinson OPICAPONA/LEVODOPA
Investigadora principal: DRA. MONICA KURTIS
BIA-91067-404 ( OCEAN ) Estudio clínico aleatorizado, controlado con placebo, doble ciego, para evaluar el efecto de opicapona 50 mg en pacientes con enfermedad de Parkinson que presentan fluctuaciones motoras de fin de dosis y dolor asociado. OPICAPONA
Investigadora principal: DRA. MÓNICA KURTIS
EPILEPSIA
PRAX-562-221: A Phase 2, Double-Blind,
Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX‑562 in Pediatric Participants with Developmental and
Epileptic Encephalopathies Followed by an Open-Label Extension. DR GIL-NAGEL
NBI-921352-DEE2013: A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) DR GIL-NAGEL
NE001: SAFETY AND THERAPEUTIC MEASURES OF TRANSCRANIAL CATHODAL DIRECT CURRENT STIMULATION (TDCS) IN PATIENTS WITH REFRACTORY FOCAL EPILEPSY. DR GIL-NAGEL
YKP509C003:
Estudio aleatorizado, controlado con placebo y doble ciego para investigar la eficacia y la seguridad del carisbamato (YKP509) como tratamiento complementario para las crisis asociadas al síndrome de Lennox-Gastaut en niños y adultos, con extensión abierta opcional DR GIL-NAGEL
XPF-010-301: A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizure DR GIL-NAGEL
XPF-010-304:
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy DR GIL-NAGEL
ALZHEIMER
M23-515: A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-552 in Participants with Mild Alzheimer’s Diseas DRA ELENA RIVA
PARKINSON
BIA 28-6156-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene DRA MÓNICA KURTIS
ZX008-1900 An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients with Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome. Fenfluramina
Investigador principal: DR GIL-NAGEL
XPF-008-201 A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy, with an Open-label Extension ( Xenon Pharmaceuticals Inc. ). XEN1101
Investigador principal: DR GIL-NAGEL
NBI-827104-CSWS2025 Long-Term, Open-Label Extension Study to Evaluate the Safety and Tolerability of NBI-827104 in Pediatric Subjects with Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep. NBI-827104
Investigador principal: DR GIL-NAGEL
TAK 935 18 001 A phase 2, Prospective, Internacional, open-label, ulti-site, extesion study to Assess the long-Term safety and Tolerability of TAK-935 as adjunctive Therapy in Patients with rare Epilepsy. TAK-935
Investigador principal: DR GIL-NAGEL
CVL-865-SZ-001 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Trial Of Cvl-865 As Adjunctive Therapy In Adults With Drug-Resistant Focal Onset Seizures (Realize Trial). CVL-865
Investigador principal: DR GIL-NAGEL
PTC743-MIT-001-EP Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects with Refractory Epilepsy. Vatiquinona
Investigador principal: DR GIL-NAGEL
PD0053 A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY PARKINSON’S DISEASE UCB0599
Investigadora principal: DRA MÓNICA KURTIS
